Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

In Hwan Bae

Tae Woo Kim

Young Gil Ahn

Kwee Hyun Suh

Jae Yul Choi

Ji Sook Kim

Ji Young Song

Seok Jong Kang

Eun Joo Kwak

Ho Seok Kim

Eun Young Byun

Seung Ah Jun

Sang Mi Han

Jung Beom Son

Young Jin Ham

Won Jeoung Kim

Seung Hyun Jung

Seo Hee Kim

Maeng Sup Kim

Chang Hee Park

Young Hee Jung

Hae Kyoung Ju

Jung Soo Nam

Mi Yon Shim

Min Jeong Kim

Provided is a compound selected from a compound of chemical formula 1 having lysine-specific demethylase-1 (LSD1) inhibitory activity, and a tautomer, a stereoisomer, and a solvate thereof, and pharmaceutically acceptable salts of the aforementioned components. The compound is effective in the prevention or treatment of diseases caused by abnormal activation of LSD1. Also disclosed is a composition containing the compound as an active ingredient and its uses in preventing and/or treating diseases caused by abnormal activation of LSD1.

Imidazopyridine derivative compounds and use of same

Provided are a pharmaceutical composition for treating acute myeloid leukemia (AML), the pharmaceutical composition containing an Fms-like tyrosine kinase (Fms-like tyrosine kinase-3: FLT3) inhibitor or a pharmaceutically acceptable salt or solvate thereof, and a hypomethylating agent (HMA) or a pharmaceutically acceptable salt or solvate thereof in a therapeutically effective combination, and a method of treating AML using the composition.

Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia

Provided are: a pharmaceutical composition for treating myeloid leukemia (AML), and a method for treating acute myeloid leukemia using same, the pharmaceutical composition comprising a therapeutically effective combination of an Fms-like tyrosine kinase-3 (FLT3) inhibitor or pharmaceutically acceptable salt or solvate thereof, and a chemotherapeutic agent or pharmaceutically acceptable salt or solvate thereof.

Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents

Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.

Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same

The present invention relates to a compound, 4-amino-N-(1-((3-chloro-2-fluoro-4-hydroxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and pharmaceutically acceptable salts thereof having inhibitory activity for protein kinases.

Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase

Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in preventing or treating a disease caused by abnormal activation of LSD1.

Pyrazole derivative compound and use thereof

Provided are a pyrimidine compound represented by Formula 1, a method of preparing the same, and a pharmaceutical use of the pyrimidine compound for the prevention or treatment of cancer.

Pyrimidine compound and pharmaceutical use thereof

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases

A compound selected from the group consisting of an isoquinoline-5-carboxamide derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate and a solvate thereof is effective for the prevention or treatment of diseases associated with abnormal cell growth, which are caused by abnormal activation of a protein kinases.

Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase

Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).

Growing community of inventors

Hwaseong-si, South Korea

In Hwan Bae